Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Kirsten L. White"'
Autor:
Danielle P. Porter, Martin Daeumer, Alexander Thielen, Silvia Chang, Ross Martin, Cal Cohen, Michael D. Miller, Kirsten L. White
Publikováno v:
Viruses, Vol 7, Iss 12, Pp 6360-6370 (2015)
At Week 96 of the Single-Tablet Regimen (STaR) study, more treatment-naïve subjects that received rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) developed resistance mutations compared to those treated with efavirenz (EFV)/FTC/TDF by populatio
Externí odkaz:
https://doaj.org/article/c566a42f2e5e40929db4628f4d50f0c5
Publikováno v:
Viruses, Vol 6, Iss 7, Pp 2858-2879 (2014)
The integrase (IN) strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), comprise the newest drug class approved for the treatment of HIV-1 infection, which joins the existing classes of reverse transcript
Externí odkaz:
https://doaj.org/article/f8b0e5c3ad46466999b343a23b818b6e
Autor:
Paul E. Sax, Kristen Andreatta, Jean-Michel Molina, Eric S. Daar, Debbie Hagins, Rima Acosta, Michelle L. D’Antoni, Silvia Chang, Ross Martin, Hui Liu, Christiana Blair, Ian McNicholl, Joel Gallant, Sean E. Collins, Hal Martin, Kirsten L. White
Publikováno v:
AIDS. 36:1511-1520
We investigated the prevalence of preexisting M184V/I and associated risk factors among clinical trial participants with suppressed HIV and evaluated the impact of M184V/I on virologic response after switching to bictegravir/emtricitabine/tenofovir a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6708a378d909f6a774c7479a369e97a4
https://doi.org/10.1097/qad.0000000000003244
https://doi.org/10.1097/qad.0000000000003244
Autor:
Michelle L, D'Antoni, Kristen, Andreatta, Rima, Acosta, Hal, Martin, Silvia, Chang, Ross, Martin, Kirsten L, White
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 89:433-440
Preexisting drug resistance limits the utility of HIV antiretroviral therapy. Studies have demonstrated safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), including in patients with M184V/I substitutions.We investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caabc81c6cca300fb63ea25894511100
https://doi.org/10.1097/qai.0000000000002888
https://doi.org/10.1097/qai.0000000000002888
Autor:
Rima K. Acosta, Michelle L. D’Antoni, Andrew Mulato, Stephen R. Yant, Tomas Cihlar, Kirsten L. White
Publikováno v:
Antimicrobial agents and chemotherapy. 66(5)
The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), dolutegravir (DTG)+FTC/TAF, DTG/lamivudine (3TC), and DTG/rilpivirine (RPV) are all approved for treatment of HIV-infected p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d37852387616aafe753d20f482e56196
https://pubmed.ncbi.nlm.nih.gov/35389236
https://pubmed.ncbi.nlm.nih.gov/35389236
Autor:
Ross Martin, Sean E Collins, Madeleine Willkom, Hal Martin, Aiyappa Parvangada, Hui Liu, Kristen Andreatta, Kirsten L. White, Rima Acosta
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 85:363-371
BACKGROUND Study 4030 was a phase 3, randomized, double-blinded study of 565 HIV-1 RNA-suppressed participants switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF. Nucleoside reverse transcriptase inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a35075ce9fd7e65fb1825f9329a63cf7
https://doi.org/10.1097/qai.0000000000002454
https://doi.org/10.1097/qai.0000000000002454
Autor:
Erin Quirk, Hui Liu, Ya-Pei Liu, Hiba Graham, Lilian Wei, Ross Martin, Silvia Chang, Madeleine Willkom, Kirsten L. White, Hal Martin, Kristen Andreatta
Publikováno v:
Journal of Antimicrobial Chemotherapy. 74:3555-3564
ObjectivesStudies 1878 and 1844 demonstrated non-inferior efficacy of switching suppressed HIV-1-infected adults to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) versus continuing boosted PI-based triple regimens or dolutegravir/abaca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1a21ada78cac5ade5dd7b5911601ada
https://doi.org/10.1093/jac/dkz347
https://doi.org/10.1093/jac/dkz347
Autor:
Anita Niedziela-Majka, Haolun Jin, Nikolai Novikov, Nathan Osman, Ernesto Cuadra-Foy, Bluma G. Brenner, Lazerwith Scott E, Kirsten L. White, Federico Campigotto, Morganelli Philip Anthony, Manuel Tsiang, Devleena Shivakumar
Publikováno v:
Antimicrobial Agents and Chemotherapy
The HIV integrase (IN) strand transfer inhibitor (INSTI) bictegravir (BIC) has a long dissociation half-life (t1/2) from wild-type IN-DNA complexes: BIC 163 h > dolutegravir (DTG) 96 h > raltegravir (RAL) 10 h > elvitegravir (EVG) 3.3 h. In cells, BI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c57ce3c14873aeaa1aafc412318bd473
https://doi.org/10.1128/aac.02406-20
https://doi.org/10.1128/aac.02406-20
Publikováno v:
Open Forum Infectious Diseases. 8:S542-S543
Background Adherence to antiretroviral therapy is important for HIV suppression. In clinical trials, adherence is commonly measured by pill count; limitations are that unreturned pills may not have been taken and unreturned pill bottle data are omitt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31ca59b1badc2cb173a9b1fa4d6b7a10
https://doi.org/10.1093/ofid/ofab466.1097
https://doi.org/10.1093/ofid/ofab466.1097
Autor:
Diana M. Brainard, Silvia Chang, Hailin Huang, Rima Acosta, Xinxin Wang, Sean E Collins, Ross Martin, Kirsten L. White, Grace Q Chen, Hal Martin
Publikováno v:
The Journal of antimicrobial chemotherapy. 76(8)
Objectives Two Phase 3, randomized, double-blind, active-controlled studies of initial HIV-1 treatment demonstrated that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was non-inferior to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC; Stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8a88cdc59848368fe13f39559807f91
https://pubmed.ncbi.nlm.nih.gov/33880558
https://pubmed.ncbi.nlm.nih.gov/33880558